Complications of biologics in inflammatory bowel disease

Current Opinion in Gastroenterology

Volumn 31, Issue 4, 2015, Pages 296-302

  Sousa, Paula ^a   Allez, Matthieu ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Adalimumab; Anti TNF monoclonal antibodies; Infection; Inflammatory bowel disease; Infliximab; Malignancy

Indexed keywords

MERCAPTOPURINE; TUMOR NECROSIS FACTOR INHIBITOR; BIOLOGICAL PRODUCT; GASTROINTESTINAL AGENT; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER PATIENT; CHEMOPROPHYLAXIS; COMBINATION CHEMOTHERAPY; DRUG SAFETY; HUMAN; INFECTION RISK; INFECTIOUS COMPLICATION; INFLAMMATORY BOWEL DISEASE; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; LYMPHOMA; OPPORTUNISTIC INFECTION; PERIOPERATIVE PERIOD; RISK ASSESSMENT; SCREENING TEST; SKIN CANCER; SURGICAL RISK; TUBERCULOSIS; VACCINATION; VIRUS INFECTION; ANTAGONISTS AND INHIBITORS; INFLAMMATORY BOWEL DISEASES; NEOPLASMS; OPPORTUNISTIC INFECTIONS; RISK FACTOR;

BIOLOGICAL PRODUCTS; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; NEOPLASMS; OPPORTUNISTIC INFECTIONS; RISK FACTORS; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA; VACCINATION;

EID: 84942573855     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0000000000000191     Document Type: Article

References (54)

1. Andersen NN, Jess T. Risk of infections associated with biological treatment in inflammatory bowel disease. World J Gastroenterol 2014;20:16014-16049.
2. Dave M, Purohit T, Razonable R, Loftus EV Jr. Opportunistic infections due to inflammatory bowel disease therapy. Inflammatory Bowel Diseases 2014;20:196-212.
3. Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn's Colitis 2014;8:443-468. The update of the ECCO consensus on opportunistic infections in IBD.
4. Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Euro Respir J 2010;36:1185-1206.
5. Ramiro S, Gaujoux-Viala C, Nam JL, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2014;73:529-535.
6. Dulai PS, Thompson KD, Blunt HB, et al. Risks of serious infection or lymphoma with antitumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review. Clin Gastroenterol Hepatol 2014;12:1443-1451; quiz e88-9.
7. Baddley JW, Winthrop KL, Chen L, et al. Nonviral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study. Ann Rheum Dis 2014;73:1942-1948.
8. Hendler SA, Cohen BL, Colombel JF, et al. High dose infliximab therapy in Crohn's disease: clinical experience, safety, and efficacy. J Crohn's Colitis 2015;9:266-275.
9. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4:621-630.
10. Kwon M, Sung M, Kwon YJ, et al. Active tuberculosis risk with tumor necrosis factor inhibitors after treating latent tuberculosis. J Clin Rheum 2014;20:68-73. Chemoprophylaxis with isoniazid and/or rifampicin is recommended in patients with latent tuberculosis infection before anti-TNF therapy. This study explored the protective effect of this chemotherapy against active tuberculosis under anti-TNF exposure.
11. Byun JM, Lee CK, Rhee SY, et al. Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-alpha inhibitor. Scandinavian J Gastroenterol 2015;50:312-320. A retrospective study cohort performed in Korea which demonstrated the high risk of tuberculosis in IBD patients receiving anti-TNF in a region with intermediate tuberculosis burden.
12. Van Der Have M, Belderbos TD, Fidder HH, et al. Screening prior to biological therapy in Crohn's disease: adherence to guidelines and prevalence of infections. Results from a multicentre retrospective study. Digestive Liver Disease 2014;46:881-886.
13. Hradsky O, Ohem J, Zarubova K, et al. Disease activity is an important factor for indeterminate interferon-gamma release assay results in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2014;58:320-324.
14. Scrivo R, Sauzullo I, Mengoni F, et al. The role of interferon-gamma release assays in predicting the emergence of active tuberculosis in the setting of biological treatment: a case report and review of the literature. Clin Rheum 2014.
15. Sester M, Sotgiu G, Lange C, et al. Interferon-gamma release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Euro Respir J 2011;37:100-111.
16. Kim YJ, Kim YG, Shim TS, et al. Safety of resuming tumour necrosis factor inhibitors in patients who developed tuberculosis as a complication of previous TNF inhibitors. Rheumatology (Oxford, England) 2014;53:1477-1481.
17. Masia M, Martinez M, Garcia-Sepulcre MF, et al. Recurrence of active tuberculosis following resumption of anti-TNF-alpha therapy in a patient with Crohn's disease. Int J Tuberc Lung Dis 2014;18:249-250.
18. Rihana NA, Kandula M, Velez A, et al. Histoplasmosis presenting as granulomatous hepatitis: case report and review of the literature. Case Rep Med 2014;2014:879535.
19. Pinheiro Bdo V, Delgado Ade A, Chebli JM. Hepatitis and pneumonitis during adalimumab therapy in Crohn disease: mind the histoplasmosis! Arq Gastroenterol 2014;51:73-76.
20. Bodro M, Carratala J, Paterson DL. Legionellosis and biologic therapies. Respir Med 2014;108:1223-1228.
21. Tung Chen Y, Perales C, Lacruz J, et al. Visceral leishmaniasis infection during adalimumab therapy: a case report and literature review. Int J Rheum Dis 2014;17:822-824.
22. Cantini F, Boccia S, Goletti D. HBV reactivation in patients treated with antitumor necrosis factor-alpha (TNF-alpha) agents for rheumatic and dermatologic conditions. Syst Rev Meta-Anal 2014;2014:926836.
23. Pompili M, Biolato M, Miele L, Grieco A. Tumor necrosis factor-alpha inhibitors and chronic hepatitis C: a comprehensive literature review. World J Gastroenterol 2013;19:7867-7873.
24. Desalermos AP, Farraye FA, Wasan SK. Vaccinating the inflammatory bowel disease patient. Expert Rev Gastroenterol Hepat 2015;9:91-102.
25. Magro F, Abreu C. Immunisations in Crohn's disease: who? why? what? when? Best Pract Res Clin Gastroenterol 2014;28:485-496.
26. Wasan SK, Calderwood AH, Long MD, et al. Immunization rates and vaccine beliefs among patients with inflammatory bowel disease: an opportunity for improvement. Inflammatory Bowel Diseases 2014;20:246-250.
27. Williams CJ, Peyrin-Biroulet L, Ford AC. Systematic review with metaanalysis: malignancies with antitumour necrosis factor-alpha therapy in inflammatory bowel disease. Aliment Pharmacol Therap 2014;39:447-458.
28. Osterman MT, Sandborn WJ, Colombel JF, et al. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease. Gastroenterology 2014;146:941-949. This pooled analysis in placebo-controlled trials of adalimumab in Crohn's disease showed no increased risk of malignancy with adalimumab in monotherapy as compared with the general population, but an increased risk of malignancy in patients who received a combotherapy.
29. Lichtenstein GR, Feagan BG, Cohen RD, et al. Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT Registry. Am J Gastroenterol 2014;109:212-223. A publication from the TREAT registry with a pooled analysis of trials of infliximab in Crohn's disease which showed no increase of malignancies in patients who received infliximab.
30. Aaltonen KJ, Joensuu JT, Virkki L, et al. Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy. J Rheumatol 2015.
31. Beaugerie L, Carrat F, Colombel JF, et al. Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. Gut 2014;63:1416-1423.
32. Beaugerie L. Use of immunosuppressants and biologicals in patients with previous cancer. Digestive Diseases (Basel, Switzerland) 2013;31:254-259.
33. Feuerstein JD, Cheifetz AS. Miscellaneous adverse events with biologic agents (excludes infection and malignancy). Gastroenterol Clin North Am 2014;43:543-563.
34. Fiorino G, Danese S, Pariente B, Allez M. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-alpha agents. Autoimmun Rev 2014;13:15-19.
35. Kip KE, Swoger JM, Grandinetti LM, et al. Tumor necrosis factor alpha antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system. Inflammatory Bowel Diseases 2013;19:1164-1172.
36. Myrelid P, Marti-Gallostra M, Ashraf S, et al. Complications in surgery for Crohn's disease after preoperative antitumour necrosis factor therapy. Br J Surg 2014;101:539-545.
37. Rosenfeld G, Qian H, Bressler B. The risks of postoperative complications following preoperative infliximab therapy for Crohn's disease in patients undergoing abdominal surgery: a systematic review and meta-analysis. J Crohn's Colitis 2013;7:868-877.
38. Selvaggi F, Pellino G, Canonico S, Sciaudone G. Effect of preoperative biologic drugs on complications and function after restorative proctocolectomy with primary ileal pouch formation: systematic review and meta-analysis. Inflammatory Bowel Diseases 2015;21:79-92.
39. Van Der Woude CJ, Ardizzone S, Bengtson MB, et al. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohn's Colitis 2014. The updated ECCO consensus on reproduction and pregnancy in IBD.
40. Khan N, Asim H, Lichtenstein GR. Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy. Exp Opin Drug Saf 2014;13:1699-1708.
41. Mozaffari S, Abdolghaffari A, Nikfar S, Abdollahi M. Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: a systematic review with meta-analysis. Hum Exp Toxicol 2014.
42. Chaparro M, Gisbert JP. How safe is infliximab therapy during pregnancy and lactation in inflammatory bowel disease? Exp Opin Drug Saf 2014;13:1749-1762.
43. Deepak P, Stobaugh DJ. Maternal and foetal adverse events with tumour necrosis factor-alpha inhibitors in inflammatory bowel disease. Aliment Pharmacol Therap 2014;40:1035-1043.
44. Guiddir T, Fremond ML, Triki TB, et al. Anti-TNF-alpha therapy may cause neonatal neutropenia. Pediatrics 2014;134:e1189-e1193. A small case series (four newborns and two pregnancies) describing severe neutropenia at birth probably related to infliximab exposure in utero.
45. Jharap B, De Boer NK, Stokkers P, et al. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease. Gut 2014;63:451-457.
46. Lin L, Liu X, Wang D, Zheng C. Efficacy and safety of antiintegrin antibody for inflammatory bowel disease: a systematic review and meta-analysis. Medicine 2015;94:e556.
47. Lobaton T, Vermeire S, Van Assche G, Rutgeerts P. Review article: antiadhesion therapies for inflammatory bowel disease. Aliment Pharmacol Therap 2014;39:579-594.
48. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699-710.
49. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013;369:711-721.
50. Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 2014;147:618-627; e3.
51. Wang MC, Zhang LY, Han W, et al. PRISMA: efficacy and safety of vedolizumab for inflammatory bowel diseases - a systematic review and meta-analysis of randomized controlled trials. Medicine 2014;93:e326.
52. Amiot A, Peyrin-Biroulet L. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Therap Adv Gastroenterol 2015;8:66-82.
53. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1665-1674.
54. Tuskey A, Behm BW. Profile of ustekinumab and its potential in patients with moderate-to-severeCrohn's disease. Clin Exp Gastroenterol 2014;7:173-179.